

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 67456

Title: Current treatment landscape for oligometastatic non-small-cell lung cancer

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05622594 Position: Peer Reviewer Academic degree: PhD

Professional title: Professor

Reviewer's Country/Territory: Japan

Author's Country/Territory: Spain

Manuscript submission date: 2021-04-25

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-04-25 22:47

Reviewer performed review: 2021-04-27 04:17

Review time: 1 Day and 5 Hours

Scientific quality	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[]Yes [Y]No
Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous



Baishideng Publishing

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568 E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Garde-Noguera and colleagues report a minireview of current treatment landscape for oligometastatic non-small cell lung cancer. This review is generally well written. I have few comments. - The authors should discuss the definition of oligometastasis in more detail, especially the criterion of number of metastases. The European multidisciplinary group is defined as 5 or less, but a lot of prospective trials in recent years have been conducted on patients with 3 or less metastatic sites. Please also introduce the data on which each definition is based. -Are there any reports of RFA or cryoablation actually being used in the treatment of oligometastatic NSCLC? If not, it may be premature for the authors to describe these procedures in this review.



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 67456

Title: Current treatment landscape for oligometastatic non-small-cell lung cancer

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05227913 Position: Peer Reviewer Academic degree: MD

Professional title: Professor

Reviewer's Country/Territory: Turkey

Author's Country/Territory: Spain

Manuscript submission date: 2021-04-25

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-04-25 14:05

Reviewer performed review: 2021-05-03 17:47

Review time: 8 Days and 3 Hours

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [Y] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Re-review	[]Yes [Y]No
Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Thank you for your good work